PURPOSE: The proof of concept for in vivo targeting of beta-amyloid plaques (Abeta) in patients with Alzheimer's disease (AD) by means of nuclear imaging methods has been shown in recent clinical studies. METHODS: For positron emission tomography (PET), the five compounds [(11)C]PIB, 3'[(18)F]FPIB, [(18)F]FDDNP, [(11)C]SB-13 and [(18)F]F-SB-13 have been developed by a formal charge neutralisation of agents used for staining of AD brain post mortem. RESULTS: In AD-patients, these compounds have been shown to possess a selective uptake in the brain regions known to have a high Abeta-load. Progress towards tracers with proportionality between tracer uptake and quantity of Abeta-load, of use for longitudinal studies of AD patients, is addressed in the current development of Abeta-tracers. CONCLUSION: Despite the extensive information on the structure-affinity relationship of several Abeta-binding compounds, data on the regional brain binding kinetics-beyond uptake in healthy rodents-have been obtained only for a few compounds. Recent results indicate that PET-imaging of Abeta-deposits in transgenic rodent models of AD is feasible which may be valuable for a more relevant preclinical evaluation of Abeta-tracers.
PURPOSE: The proof of concept for in vivo targeting of beta-amyloid plaques (Abeta) in patients with Alzheimer's disease (AD) by means of nuclear imaging methods has been shown in recent clinical studies. METHODS: For positron emission tomography (PET), the five compounds [(11)C]PIB, 3'[(18)F]FPIB, [(18)F]FDDNP, [(11)C]SB-13 and [(18)F]F-SB-13 have been developed by a formal charge neutralisation of agents used for staining of AD brain post mortem. RESULTS: In AD-patients, these compounds have been shown to possess a selective uptake in the brain regions known to have a high Abeta-load. Progress towards tracers with proportionality between tracer uptake and quantity of Abeta-load, of use for longitudinal studies of ADpatients, is addressed in the current development of Abeta-tracers. CONCLUSION: Despite the extensive information on the structure-affinity relationship of several Abeta-binding compounds, data on the regional brain binding kinetics-beyond uptake in healthy rodents-have been obtained only for a few compounds. Recent results indicate that PET-imaging of Abeta-deposits in transgenic rodent models of AD is feasible which may be valuable for a more relevant preclinical evaluation of Abeta-tracers.
Authors: Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price Journal: J Nucl Med Date: 2005-12 Impact factor: 10.057
Authors: Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio Journal: N Engl J Med Date: 2006-12-21 Impact factor: 91.245
Authors: Hiroshi Toyama; Daniel Ye; Masanori Ichise; Jeih-San Liow; Lisheng Cai; David Jacobowitz; John L Musachio; Jinsoo Hong; Mathew Crescenzo; Dnyanesh Tipre; Jian-Qiang Lu; Sami Zoghbi; Douglass C Vines; Jurgen Seidel; Kazuhiro Katada; Michael V Green; Victor W Pike; Robert M Cohen; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2005-03-25 Impact factor: 9.236
Authors: Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk Journal: J Med Chem Date: 2003-06-19 Impact factor: 7.446
Authors: Masahiro Ono; Alan Wilson; Jose Nobrega; David Westaway; Paul Verhoeff; Zhi-Ping Zhuang; Mei-Ping Kung; Hank F Kung Journal: Nucl Med Biol Date: 2003-08 Impact factor: 2.408
Authors: Nicolaas P L G Verhoeff; Alan A Wilson; Shinichiro Takeshita; Liat Trop; Doug Hussey; Kernjit Singh; Hank F Kung; Mei-Ping Kung; Sylvain Houle Journal: Am J Geriatr Psychiatry Date: 2004 Nov-Dec Impact factor: 4.105
Authors: Alexander Drzezga; Timo Grimmer; Martin Peller; Marc Wermke; Hartwig Siebner; Josef P Rauschecker; Markus Schwaiger; Alexander Kurz Journal: PLoS Med Date: 2005-09-20 Impact factor: 11.069
Authors: Yajing Liu; Lin Zhu; Karl Plössl; Seok Rye Choi; Hongwen Qiao; Xiaotao Sun; Song Li; Zhihao Zha; Hank F Kung Journal: Nucl Med Biol Date: 2010-06-29 Impact factor: 2.408
Authors: Behrooz H Yousefi; Alexander Drzezga; Boris von Reutern; André Manook; Markus Schwaiger; Hans-Jürgen Wester; Gjermund Henriksen Journal: ACS Med Chem Lett Date: 2011-07-19 Impact factor: 4.345
Authors: Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Maria C Carrillo; Dean M Hartley; Saima Hedrick; Virginia Pappas; William H Thies Journal: Alzheimers Dement Date: 2013-01 Impact factor: 21.566